Amgen Inc (AMGN)

pos +0.00
Today's Range: 0.00 - 0.00 | AMGN Avg Daily Volume: 3,441,300
Last Update: 01/28/15 - 4:00 PM EST
Volume: 0
YTD Performance: -2.92%
Open: $0.00
Previous Close: $154.64
52 Week Range: $108.20 - $173.14
Oustanding Shares: 760,670,000
Market Cap: 120,862,856,300
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 5 5
Moderate Buy 2 2 2 2
Hold 8 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.17 2.11 2.11 2.11
Latest Dividend: 0.79
Latest Dividend Yield: 1.99%
Dividend Ex-Date: 02/10/15
Price Earnings Ratio: 18.26
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
18.26 25.00 25.85
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-1.62% 28.12% 126.28%
Revenue 8.20 0.24 0.07
Net Income 16.90 0.10 0.03
EPS 20.30 0.40 0.12
Earnings for AMGN:
Revenue 18.68B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $2.05 $2.42 $9.35 $10.50
Number of Analysts 3 3 12 9
High Estimate $2.09 $2.57 $9.96 $11.70
Low Estimate $2.03 $2.33 $9.15 $9.95
Prior Year $1.86 $2.37 $8.68 $9.35
Growth Rate (Year over Year) 10.22% 2.25% 7.70% 12.37%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

Braving Biotech Real Money Pro($)

Do you need to pick one name?
They are prone to being whipsawed by news.
Jan 06, 2015 | 7:48 AM EST
AMGN was initiated with an Equal-weight rating, Barclays said. Company will struggle to sustain the momentum from 2014. $180 price targ...
Jan 05, 2015 | 6:34 AM EST
AMGN was downgraded to Equal-weight from Overweight, Morgan Stanley said. $177 price target. Valuation call, as the company lacks near-...

Right and Wrong Real Money Pro($)

Every trade should have a thesis and a catalyst.

2 Names Top My Watch List Real Money Pro($)

Why I'm looking at the iShares Biotech ETF and Amgen.
A litany of reasons why you should calm your nerves.
In this era of turmoil, investors can take comfort in this sector.
Oct 29, 2014 | 6:28 AM EDT
AMGN was upgraded from Neutral to Buy, Nomura said. $193 price target. Company has cut costs and can expand the operating margin by 15 ...

This Morning's Market Setup Real Money Pro($)

Where it began.

Columnist Conversations

Kulicke & Soffa(+7%)is in full breakout mode today. The stock opened with an upside gap that pushed ...
Seemed as if comments related to inflation were a table setter in pushing out the first rate increase until th...
While many are concerned about a negative reaction if the Fed doesn't hint at pushing out interest rate hikes ...
We are nearly to the Fed decision and this time around expectations for what's to come are rather muted. No m...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.